Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labetalol hypertension study

Executive Summary

Report compiled by medical economist Gerry Oster of Brookline, Mass.-based Policy Analysis Inc. concludes that the alpha-beta blocker is more cost-effective than the beta blocker propanolol in treating black adults with mild-to-moderate hypertension. Oster maintains that for every 1,000 patients on monotherapy, those taking labetalol would have two to seven fewer strokes over a 10-year period, depending on age and sex, with a $190-$212 reduction in the yearly cost of treatment compared to propranolol. Oster reported the findings at a March 22 science writers seminar in New York City. Labetolol is marketed in the U.S. by Glaxo under the Trandate brand and by Schering as Normodyne.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS013414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel